Emgality ® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Emgality® ▼ (galcanezumab): Use in Pediatric Patients

The safety and effectiveness of galcanezumab in patients below the age of 18 have not been established

Information from the label

The safety and efficacy of galcanezumab in children aged 6 to 18 years have not yet been established. No data are available.1

There is no relevant use of galcanezumab in children below the age of 6 years for the prevention of migraine.1

Clinical Trial Information

Patients <18 years of age at the time of screening were excluded from participation in the galcanezumab phase 2 and phase 3 clinical trials for migraine prevention.2-5

As such, the safety and efficacy of galcanezumab in patients younger than 18 years of age have not been established.

The REBUILD-1 and REBUILD-2 studies are designed to evaluate the safety and efficacy of galcanezumab in children and adolescents. Additional information on these studies are provided below.

REBUILD-1

The REBUILD-1 study is a phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of galcanezumab in children

  • 6 to 17 years of age

  • with a diagnosis of episodic migraine with or without aura as defined by the International Headache Society ICHD-3 guidelines (meeting criteria 1.1 or 1.2), and

  • with a history of migraine headaches of at least 6 months prior to screening.6-8

REBUILD-2

The REBUILD-2 study is a phase 3, randomized, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of galcanezumab versus placebo for preventive treatment of chronic migraine in adolescents

  • 12 to 17 years of age, and

  • diagnosed with chronic migraine, defined by the ICHD-3 guidelines (meeting criteria 1.3) as a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month.6,9,10

Therapeutic Indication

Galcanezumab is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1

References

1. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. http://dx.doi.org/10.1001/jamaneurol.2018.1212

3. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. http://dx.doi.org/10.1177/0333102418779543

4. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. http://dx.doi.org/10.1212/WNL.0000000000006640

5. Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187-193. http://dx.doi.org/10.1001/jamaneurol.2017.3859

6. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. http://dx.doi.org/10.1177/0333102417738202

7. A randomized, double-blind, placebo-controlled study of galcanezumab in patients 6 to 17 years of age with episodic migraine – the REBUILD-1 study. ClinicalTrials.gov. March 14, 2018. Accessed November 16, 2020. https://www.clinicaltrials.gov/ct2/show/NCT03432286

8. A study of galcanezumab (LY2951742) in participants 6 to 17 years of age with episodic migraine. Lilly Trial Guide website. Accessed November 16, 2020. https://trials.lillytrialguide.com/en-US/trial/3ZYuzhkEA0eK8qoWk6AUq2?conditionId=6aDBwPt6LDJj9rB2qnG4O7

9. A randomized, double-blind, placebo-controlled study of galcanezumab in adolescent patients 12 to 17 years of age with chronic migraine - the REBUILD-2 study. ClinicalTrials.gov. November 11, 2020. Accessed November 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04616326

10. A study of galcanezumab (LY2951742) in participants 12 to 17 years of age with chronic migraine (REBUILD-2). Lilly Trial Guide Website. Accessed November 16, 2020. https://trials.lillytrialguide.com/en-US/trial/1mozTDMc0KoyNzh7Twsl5c?conditionId=6aDBwPt6LDJj9rB2qnG4O7

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: November 16, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request